INNOGEN-B (02591): Received approval from the National Medical Products Administration to conduct Phase Ib clinical trials of liraglutide for the treatment of adolescent obesity.

12:44 22/06/2026

Yinuo Medicine-B (02591) announced that on June 17, 2026, the group has received approval from the China National Medical Products Administration to conduct Phase Ib clinical trials of the group's use of Supaglutide for the treatment of adolescent obesity. The company expects the clinical trial to begin in July 2026 and plans to recruit approximately 36 participants for the trial.

INNOGEN-B (02591) announced that on June 17, 2026, the group has received approval from the China National Medical Products Administration to conduct phase Ib clinical trials for the use of Isubpaglutide in treating adolescent obesity. The company expects the clinical trial to begin in July 2026 and plans to recruit approximately 36 participants for the trial.

New Stock Preview | From secondary equipment of power grid to energy storage and AI data center, where is the transformation story of Beijing Sifang Automation at?

HK Stock Market Move | Inland insurance stocks collectively rebounded. The Shanghai Lujiazui Finance & Trade Zone Development forum released multiple significant signals. Institutions are optimistic about the repair brought by high growth in the second quarter performance.

HK Stock Market Move | QINGSONG HEALTH (02661) rose more than 20% in the afternoon recently, and signed a three-year strategic cooperation memorandum with Basel Medical to jointly develop the Southeast Asian market.

New Stock Preview | From secondary equipment of power grid to energy storage and AI data center, where is the transformation story of Beijing Sifang Automation at?